Abstract
Matrix metalloproteinases (MMP) play critical roles in a variety of immune reactions by facilitating cell migration, and affect cell communication by processing both cytokines and cell surface receptors. Based on published data indicating that MMP-9 is upregulated upon T cell activation and also in the thymus upon the induction of negative selection, we investigated the contribution of MMP-9 into mouse T cell development and differentiation in the thymus. Our data suggest that MMP-9 deficiency does not result in major abnormalities in the development of any conventionally selected or agonist selected subsets and does not interfere with thymocyte apoptosis and clearance, and that MMP-9 expression is not induced in immature T cells at any stage of their thymic development.
Similar content being viewed by others
Introduction
Gelatinase B/matrix metalloproteinase-9 (MMP-9) is a calcium-dependent, zinc-containing endopeptidase involved into the remodeling of extracellular matrix in a wide variety of biological phenomena, and an increasing body of evidence suggests that it plays an important role in the regulation of multiple immune processes1,2. It has been well documented that processing of extracellular matrix by MMP-9 is crucial for movement through and invasion into tissues by multiple cell types, including cancer cells, neutrophils, macrophages, dendritic and T cells3,4,5,6,7,8,9,10. MMP-9-mediated cleavage has also been shown to regulate the activity of a number of cytokines and chemokines11,12,13,14,15,16. MMP-9-deficient mice display elevated levels of autoantibodies to a variety of antigens17. A growing body of evidence also indicates that MMP-9 may play a more direct role in the regulation of T cell activation, although the data remain highly fragmented. Cleavage of ICAM-1 by MMP-9 protects cultured breast cancer cells from NK cell-mediated cytotoxicity18. It is likely that the same mechanism may also provide immunosuppressive input in both conventional and regulatory T cell-mediated responses since LFA-1 interaction with ICAM-1 is crucial for immune synapse stabilization and T cell activation19. Indeed, MMP-9 deficiency results in reduced recruitment of T cells and macrophages and attenuated pathology in experimental glomerulonephritis5. Another possible role for MMP-9 arises from the observation that MMP-9 produced by cancer cells cleaves CD25 expressed on the surface of tumor-infiltrating T cells and reduces their proliferation in vitro20, suggesting that a similar mechanism may downregulate T cell activation in vivo by limiting T cell reactivity to IL-2. Chemical inhibition of MMP-9 reduces proliferation of regulatory T cells in the presence of CD3/CD28-coated microbeads in vitro, although puzzlingly so does the addition of recombinant MMP-9 in the same study21. Finally, both human and mouse T cells and T cell lines have been shown to express and secrete active MMP-9 in response to antigenic stimulation22,23,24, upon chemical stimulation25,26,27,28, in response to tumors29, and downstream of cell adhesion-related signals30,31, although the regulation and biological significance of T cell intrinsic production of MMP-9 remain poorly understood. In addition, purity analysis of MMP-9-producing cell populations has not been fully reported in multiple studies.
Direct attempts to evaluate the involvement of MMP-9 into T cell activation by comparing MMP-9-sufficient and -deficient peripheral T cell responses have yielded conflicting data. Using mixed lymphocyte reaction assays, two studies from the same group reported an increased proliferation of MMP-9-deficient T cells upon stimulation with Balb/c dendritic cells, and increased production of IL-12 and IFNγ32,33. Intriguingly, the authors also observed increased proliferation of wild-type T cells derived from mice stimulated by MMP-9-deficient dendritic cells in mixed lymphocyte reaction, as compared to stimulation with wild-type DC. These data appear to suggest that MMP-9 activity suppresses T cell activation regardless of cell type of origin. In agreement with this conclusion, addition of recombinant MMP-9 to effector T cells stimulated with CD3/CD28-coated beads strongly suppressed their proliferation21. However, a later study has revealed a dramatic decrease in the proliferation of MMP-9 knockout T cells as well as in IL-2 and CD25 production in response to stimulation with anti-CD3 antibody23. The reasons behind these discrepancies remain to be experimentally addressed.
Odaka and colleagues (2005) reported a transient increase in the expression of MMP-9 in thymic tissue of Balb/c mice 16–24 hours after a single i.p. injection of CD3ε antibody mimicking negative selection34. Elevated MMP-9 production coincided with the exposure of cryptic epitopes of collagen IV as revealed by HUIV26 antibody staining, and with increased neovascularization of the thymus34. In a separate study, application of the broad spectrum MMP inhibitor GM6001 was shown to delay TCR rearrangement, inhibit the proliferation and progression of thymocytes from CD4−CD8− (double negative, DN) to CD4+CD8+ (double positive, DP) stage in ex vivo thymocyte development assays35. Finally, our own data indicated that MMP-9 deficiency combined with lpr mutation in the Fas gene resulted in thymic hyperplasia17. Based on these data, we decided to systematically analyze the requirement for MMP-9 during thymic T cell development, and induction of MMP-9 expression in developing thymocytes in response to stimulation.
Materials and Methods
Mice
Experimental protocols were approved by the Ethische Commissie Dierproeven, KU Leuven, animal protocol number B277-2014, laboratory license LA1210251 (Belgium). Animal use was in accordance with institutional permits and KU Leuven ethics policies. MMP-9-deficient mice and MMP-9−/−FasLpr mice were described previously17. Here, we used MMP-9−/− after 13 backcrosses into the C57BL/6J strain. MMP-9-sufficient C57BL/6J and FasLpr control mice were bred and housed in the same vivarium under exactly the same environmental conditions for several years. Photographic images were taken using a Canon EOS3200 camera equipped with a stabilized objective Canon EFS 18–55.
Antibodies, flow cytometry, and immunohistochemistry
The following antibodies were used for flow cytometry: CD4 (GK1.5), CD5 (53–7.3), CD8β (H35-17.2), CD25 (7D4), CD44 (IM7), F4/80 (BM8), Gr.1 (1A8-Ly6g), TCRβ (H57-597), γδTCR (GL-3), all at 2 μg/ml, and Foxp3 (FJK-16s) at 5 μg/ml, all from either eBioscience or BD Biosciences. Goat polyclonal antibody against MMP-9 antibody used in flow cytometry (2 μg/ml) and immunohistochemistry experiments (2 μg/ml) was from R&D Systems (cat. # AF909). Intracellular staining for MMP-9 was performed using Intracellular Fixation and Permeabilization Buffer Set (eBioscience) and anti-goat secondary antibody labeled with AlexaFluor 647, used at 0.5 μg/ml (ThermoFisher Scientific). Data were acquired on BD LSR Fortessa X-20 flow cytometer and analyzed using FlowJo software, version 7.6.5. Iba1 antibody used for immunohistochemistry was from Wako, used 1:200 (cat. # 019-19741). Immunohistochemical stainings were carried out on a Ventana Ultra staining platform according to manufacturer’s instructions (Roche).
Thymocyte apoptosis and deletion assays
For in vivo induction of thymocyte deletion, three to four 4–5 week old mice per genotype were injected i.p. with 50 μg of anti-CD3ε antibody (clone 145-2C11, purified, sodium azide-free, low endotoxin, BD Biosciences) in 200 μl of sterile PBS, and one sex- and age-matched mouse was injected with 200 μl of sterile PBS. Mice were sacrificed 18 or 72 h post injection. In total, 13–14 CD3ε-injected and 4 PBS-injected mice were used per genotype in four independent injection experiments. For in vitro induction of apoptosis, thymi were isolated from 4–5 week old mice, and thymocytes were isolated by pressing the tissue through 70 μm cell strainers (BD). Cells were counted and incubated at 37 °C in 96-well, flat-bottom plates in the presence of CD3/CD28-coated magnetic beads (ThermoFisher Scientific). Cells were harvested after 18 h and analyzed for activation of caspase 3 using CaspGLOW Fluorescein Active Caspase-3 Staining Kit (FITC-VAD-FMK, eBioscience) and for surface expression of Annexin V using Annexin V Apoptosis Detection Kit (eBioscience). Analysis of apoptosis by flow cytometry was performed as described36,37.
Electron microscopy
For morphological analysis, thymi were fixed in 2.5% glutaraldehyde, 4% formaldehyde, 0.2% picric acid, in 0.1 M sodium cacodylate buffer (pH 7.4) and stored in the same fixative at 4 °C. Samples were embedded in 3% agarose and sectioned at 150 μm using a vibratome. Sections were postfixed in 1% osmium tetroxide, 1.5% potassium ferrocyanide for 30 min at room temperature, stained with 0.2% tannic acid for 20 min, fixed with 1% osmium tetroxide for 30 min, stained with 1% thiocarbohydrazide for 20 min, and incubated again with 1% osmium tetroxide for 30 min. Samples were contrasted with 0.5% uranyl acetate in 25% methanol overnight at 4 °C and with Walton’s lead acetate for 30 min at 60 °C. After ethanol dehydration, samples were infiltrated and embedded into Agar 100. Blocks were sectioned at 110 nm using a Leica UCT ultra-microtome, collected onto Cu-grids coated with formvar/carbon, and imaged using JEOL JEM1400 transmission electron microscope operated at 80 kV and equipped with an 11-MP Olympus Quemesa camera.
For immunoelectron microscopy, thymi were fixed in 4% formaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) and stored in the same fixative at 4 °C. Samples were embedded in 3% agarose, sectioned at 150 μm using a vibratome, and small discs were punched out of the sections for freeze-substitution in a Leica AFS2 apparatus. The starting point was at 0 °C in 30% ethanol for 30 min, then lowered to −15 °C to −30 °C in 50% ethanol for 30 min, −30 °C to −35 °C in 75% ethanol for 30 min, and at −35 °C ethanol was replaced with acetone for 1 h. Samples were stained with 0.2% uranyl acetate in acetone for 4 h, washed 3x in acetone, and infiltrated with lowicryl HM20 at −35 °C for 48 h. UV polymerization was initiated for 24 h at −35 °C, then temperature was raised to 20 °C at a rate of 1 degree/h, together with UV polymerization. Blocks were sectioned at 110 nm using a Leica UCT ultra-microtome, and sections were collected on Ni-grids coated with formvar/carbon. Immunostaining was performed as described38. Anti-MMP-9 antibody AF909 was used at 1:30, and anti-goat immunoglobulins coupled to 10-nm gold particles (EMS) were used at 1:100. Sections were counterstained with uranyl acetate and lead citrate and imaged as above.
Zymography
Frozen thymi were thawed on ice, homogenized, lysed, purified by gelatin-Sepharose affinity chromatography, separated by gel electrophoresis, and analyzed by gelatin zymography as described previously39,40. As an internal control (IC), a known amount of recombinant human proMMP-9ΔOGHem (MMP-9 deletion mutant lacking hemopexin and O-glycosylation domains) was added to each sample. For the analysis of MMP-9 production in ex vivo stimulated cells, stimulations were carried out in serum-free synthetic medium (TexMACS, Miltenyi Biotec) for indicated periods of time, and supernatants were frozen at −80 °C. Thawed samples were purified and analyzed as above. Band densitometry was performed using ImageJ ver. 1.51a modules “Plot Lanes” and “Wand/Tracing Tool” in photographic images of Coomassie Blue-stained zymography gels rotated 0–5° to produce near-vertical bands and cropped to the shown area. No other image manipulations such as brightness or contrast adjustments were performed.
Results
Thymic T cell development in the absence of MMP-9
In agreement with published data, MMP-9 deficiency alone did not result in any obvious abnormalities in thymic size and gross morphology (refs. 17,34 and Fig. 1a–c), although there was an approx. 10% increase in thymic cellularity (Fig. 1d).
The percentage and composition of immature, CD4/CD8-double negative thymocytes were indistinguishable between MMP-9-sufficient and -deficient mice (Fig. 1e). Proportions of double-positive and single-positive lymphocytes were also identical (Fig. 1f), suggesting an absence of defects in either positive or negative selection. Next, we analyzed the abundance of rare thymocyte populations surviving strong selecting signals and giving rise to agonist-selected subsets. Regulatory T cell precursors were detected within the CD4 single positive population with the use of Foxp3 and CD25 staining (Fig. 2a), and γδ T cell precursors were detected within CD4/CD8-double negative subset by direct staining with a γδTCR antibody (Fig. 2b). The thymocyte subset containing precursors of intraepithelial CD8αα lymphocytes was revealed using TCRαβ and CD5 antibody staining and enumerated within the double negative subset as described41 (Fig. 2c). Percentages of precursors of γδ T cells and intraepithelial CD8αα cells were identical, whereas precursors of regulatory T cells displayed a minor (<10%) but reproducible decrease in MMP-9 knockout thymi (Fig. 2d).
In order to test the potential input of MMP-9 into thymocyte apoptosis and clearance during negative selection, we tested the effects of CD3ε antibody treatment in vivo and in vitro. Incubation of thymocytes with magnetic beads coated with antibodies against CD3 and CD28 resulted in massive apoptosis, as indicated by annexin V-positive and activated caspase 3-positive staining (Fig. 3A). The onset and magnitude of cell death were indistinguishable between MMP-9-sufficient and -deficient samples, indicating that MMP-9 is not required for thymocyte apoptosis in response to strong stimulation. Because MMP-9 function has been associated with macrophage activity, we then analyzed the clearance of apoptotic thymocytes in vivo. We injected MMP-9-sufficient and -deficient mice i.p. with anti-CD3ε antibody as described in Materials and Methods, and analyzed thymic deletion after 48 hours. In both cohorts, double-positive thymocytes were effectively cleared, indicating the lack of requirement for MMP-9 activity (Fig. 3b,c). Dulling of surface coreceptors occurred efficiently in both cohorts (data not shown). In light of our previous data indicating a potential synergy between MMP-9 and Fas in the thymus17, we also analyzed thymocyte deletion in mice in which the Fas mutation lpr was present. In these animals, thymocyte deletion was also unaffected by MMP-9 deficiency (Fig. 3b,c). In all cohorts, CD3ε antibody injection led to a transient weight loss and stress behaviors which are known to be caused by systemic cytokine storm and dehydration. Percentage of weight loss was similar between all genotypes (Fig. 3d).
Morphological analysis of thymocyte apoptosis upon in vivo application of CD3ε antibody did not reveal any differences between MMP-9-sufficient and -deficient mice. Ultrastructural analysis revealed a massive increase in apoptotic events, as indicated by highly compact, dark, and deformed nuclei, degradation of cell membranes, and autophagy events in the cytoplasm (Fig. 4). Thymocyte phagocytosis events were rare but present in both genotypes (Fig. 4).
Expression of MMP-9 in the thymus
Because earlier works detected the presence of MMP-9 in thymic tissue, we were interested in identifying cell populations responsible for its expression, particularly among T cell subsets. We confirmed the upregulation and activation of MMP-9 in the thymus following i.p. CD3ε antibody injection (Fig. 5a). It is noteworthy that the upregulation of MMP-9 after stimulation coincided with a reduction of MMP-2 signal, which occurred in both MMP-9-sufficient MMP-9-deficient tissue. A drop in MMP-2 may reflect its active downregulation upon stimulation, or may be indicative of a decrease in the abundance of producing cells. Critically, isolated thymocytes stimulated with CD3/CD28 beads did not produce MMP-9 after 4 h in vitro (Fig. 5b). No upregulation was detected after 1, 2, or 18 h in vitro stimulation (not shown). Furthermore, MMP-2 signal remained unchanged after in vitro stimulation, suggesting that the effect observed in the total thymus (Fig. 5a) is most likely attributable to cells of non-T lineage. Immunohistochemical analysis revealed strong and specific MMP-9 reactivity associated with a small number of round cells enriched in the thymic cortex, and specifically excluded from Iba1-positive cells of dendritic morphology which include cortical and medullar stromal cells and macrophages42 (Fig. 5c). In mice injected with CD3ε antibody, MMP-9 displayed a similar distribution pattern although the number of MMP-9-positive cells was increased (Fig. 5c). MMP-9-deficient tissue exhibited non-specific staining of cells attached to the outside of the thymic capsule, and weak diffuse staining of the capsule-proximal cortex, but not of any intrathymic cells (Fig. 5d).
In order to identify the MMP-9-positive cells, we first validated a commercial polyclonal anti-MMP-9 antibody (see Materials and Methods) for intracellular staining combined with flow cytometry. The antibody strongly stained Gr.1high cells in bone marrow (Fig. 6a) and lymph nodes (data not shown) of wild type mice. In the thymus, the immunoreactivity was exclusively present in a small population of Gr.1high, CD4/CD8 double-negative cells corresponding to either thymus-resident neutrophils or neutrophils confined within intrathymic blood vessels43 (Fig. 6b), and no immunoreactivity was associated with any T cell precursor subset including single- or double-positive thymocytes. These findings were further confirmed by immunoelectron microscopy which readily detected MMP-9 in perivascular cells, in the lumen of thymic vessels (Fig. 7a), and in tissue-resident polymorphonuclear leukocytes (Fig. 7b) but did not reveal MMP-9 reactivity in apoptotic or non-apoptotic thymocytes from anti-CD3ε injected or non-injected mice.
Discussion
Development of immature T cells in the thymus involves a series of stimulatory interactions with thymus-resident cells which are necessary for the survival, proliferation, and selection of T cells and ultimately for the formation of a functional T-cell repertoire44. During positive selection, interactions with weak self-ligands provide tonic signals required for survival, and the lack of such stimuli, e.g. in immature T cells expressing dysfunctional T cell receptors, results in death by neglect. Conversely, during negative selection interactions with strong self-ligands result in the induction of apoptosis and are required for the elimination of self-reactive clones from the mature T cell repertoire. Specific small subsets of immature T cells can survive strong stimulation by self-antigens in the thymus, and develop into several highly specialized, “agonist-selected” cell types, such as regulatory T cells and several others45. Changes in the cellular perception of selecting signals lead to profound developmental abnormalities and can result in immune deficiencies and autoimmunity. Dampening of T cell receptor signaling by the adaptor protein Themis and tyrosine phosphatase Shp-1 has been shown to establish the survival threshold between positive and negative selection, and lack of either of these molecules severely reduced thymic output due to increased signaling in response to weak ligands and increased negative selection37,46,47. Interference with thymocyte apoptosis results in the survival of self-reactive T cell specificities and leads to autoimmune manifestations48. Deletion of the transcription factor Aire which is required for the expression of non-thymic antigens by thymic epithelial cells causes a restriction in the repertoire of self-antigens available for negative selection and manifests in a systemic autoimmune syndrome49,50.
Stimulation of developing thymocytes by systemic application of anti-CD3ε antibody mimics the extreme case of negative selection in TCR-polyclonal mice and results in massive induction of thymocyte death in vivo and in vitro51,52. Apoptotic cells in the thymic cortex closely associate with macrophages which are actively recruited to the thymus following stimulation by antibody53. Published data indicated an increase in MMP-9 expression in the thymus following CD3ε antibody injection, although specific increase in developing T cells was not reported34. Because developing thymocytes are the major subset responding to CD3ε stimulation in the thymus, we hypothesized that these cells may upregulate MMP-9. The biological significance of such upregulation could rely on generation of additional peptides for selection, processing of cell surface receptors and subsequent modification of cellular signaling, regulation of cell contact duration, or other mechanisms.
We have previously reported that the deletion of MMP-9 in mice harboring the lpr mutation in the Fas gene resulted in an increase in thymus size, although it remains unknown if this effect is due to increased proliferation in the thymus, less efficient selection, or other mechanisms17. Fas is expressed in thymocytes54, acts in cis55, and is important for cell clearance in both positive and negative selection56,57,58, although it appears to be involved in the elimination of a relatively small percentage of selected thymocytes and only in response to relatively weak negatively selecting signals56,59,60,61. A separate Fas-independent, Bim-dependent mechanism has been shown to be activated in conjunction with negative selection62,63,64. Intriguingly, at least one matrix metalloproteinase, MMP-7/matrilysin cleaves both Fas and FasL65,66. MMP-7-mediated cleavage of Fas reduces susceptibility of target cells to apoptosis induced by cytotoxic T cells, Fas antibody, and chemical stimuli65,66,67, whereas cleavage of membrane-associated FasL produces a soluble fragment which is biologically active in inducing target cell apoptosis68. Enhancement of thymus hyperplasia in FasLpr mice by MMP-9 deficiency hinted to the possibility of involvement of the latter into thymocyte clearance.
We have extensively tested both hypotheses by comparing thymocyte development in mice sufficient and deficient for MMP-9. Our data clearly suggest that thymocyte development does not require MMP-9 activity. All thymic subsets were represented at appropriate proportions in MMP-9-deficient mice, with an exception of a <10% decrease in regulatory T cell percentage, and in vitro stimulation of thymocytes from both mouse cohorts revealed no differences in developmental outcomes. Perhaps more surprisingly, MMP-9 deficiency did not result in any abnormalities in the clearance of apoptotic thymocytes in mice both in C57BL/6 mice and FasLpr mice. A small increase in thymic cellularity and a small decrease in thymic regulatory T cell percentage suggest that an MMP-9-dependent mechanism may play an accessory role in the agonist selection of this particular subset and in thymocyte proliferation. One candidate molecule is TGFβ which can be released from its latent precursor form by MMP-9-mediated cleavage12. However, while TGFβ is central to the peripheral conversion and maintenance of regulatory T cells, T cell-specific deletion of Tgfbr2 gene revealed no changes in the thymic development of this subset or in fact any αβ T cell subset, or indeed in thymic cellularity69. It is also important to notice that the small increase in thymic cellularity in MMP-9 knockout mice does not translate into an increase in cellularity in peripheral lymphoid organs17.
We further concluded that developmental signaling in the thymus does not result in detectable T cell-intrinsic upregulation of MMP-9 expression. While MMP-9 was readily detected in thymic neutrophils, no T cell subset revealed MMP-9 reactivity in either flow cytometry or immunohistochemistry assays. In vitro stimulation of isolated thymocytes with CD3/CD28-coated microbeads did not result in upregulation of MMP-9 levels, as demonstrated in zymography experiments.
MMP-9 expression in thymic tissue and its upregulation upon CD3ε antibody injection has been described before, and correlated with neovascularization of the thymus34. The authors of that study hypothesized that this mechanism may increase the abundance of macrophages required for the clearance of apoptotic thymocytes. While this may indeed be the case, the functional consequences of MMP-9 dependent neovascularization and additional macrophage influx appear negligible as the lack thereof does not lead to any differences in thymocyte elimination. While more research is needed to better understand the importance of MMP-9 for the biology of thymic macrophages and neutrophils, our data suggest that its role is unrelated to thymocyte development and differentiation. The increased abundance of MMP-9-positive cells after stimulation in vivo but not in vitro suggests an influx of MMP-9-expressing cells from the bloodstream rather than induction of expression in a thymus-resident population.
Multiple matrix metalloproteinases have been implicated in thymocyte development and homeostasis. Similarly to MMP-9, stromelysins MMP-3, -10, and -11 are induced in thymi of mice injected with CD3ε antibody, and at least one of these, MMP-11 was detected in macrophages associated with apoptotic thymocytes70. Membrane-associated MMP-14 is upregulated in human thymocytes incubated on laminin-5 and implicated in the generation of soluble fragment of CD44 thought to induce migration71. MMP-19 has been shown to promote thymocyte proliferation specifically in young mice, where its deletion led to a partial block in DP-SP transition72. Activity of thymic plasmin which is known to process multiple matrix metalloproteinases including the aforementioned MMP-373, MMP-1174, and MMP-1475, as well as MMP-976, is increased upon CD3ε antibody injection34. A concerted action of MMP-9 and other matrix metalloproteinase(s) such as MMP-11, -14, -19, or other may result in functional redundancy and mask a phenotype of a single MMP knockout. As a final remark, care should be taken when interpreting thymus-specific effects of CD3ε antibody injections on non-T cell subsets which are also highly represented in the bloodstream and peripheral lymphoid organs. Massive cytokine storm caused by antibody-mediated T cell activation77 is very likely to strongly affect thymic subpopulations of non-T cells and non-thymus resident T cells, e.g. those located within thymic blood vessels.
Additional Information
How to cite this article: Gounko, N. V. et al. Thymocyte development in the absence of matrix metalloproteinase-9/gelatinase B. Sci. Rep. 6, 29852; doi: 10.1038/srep29852 (2016).
References
Vandooren, J., Van den Steen, P. E. & Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48, 222–272, 10.3109/10409238.2013.770819 (2013).
Opdenakker, G., Van den Steen, P. E. & Van Damme, J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 22, 571–579 (2001).
Agrawal, S. et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203, 1007–1019, 10.1084/jem.20051342 (2006).
Chou, C. H. et al. MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis. Oncogene 31, 458–468, 10.1038/onc.2011.240 (2012).
Kluger, M. A. et al. Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney Int 83, 865–877, 10.1038/ki.2012.483 (2013).
Yen, J. H., Kong, W. & Ganea, D. IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol 184, 3478–3486, 10.4049/jimmunol.0902542 (2010).
Osman, M., Tortorella, M., Londei, M. & Quaratino, S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology 105, 73–82 (2002).
Vermaelen, K. Y. et al. Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J Immunol 171, 1016–1022 (2003).
D’Haese, A. et al. In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J Interferon Cytokine Res 20, 667–674, 10.1089/107999000414853 (2000).
Kobayashi, Y., Matsumoto, M., Kotani, M. & Makino, T. Possible involvement of matrix metalloproteinase-9 in Langerhans cell migration and maturation. J Immunol 163, 5989–5993 (1999).
Schönbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161, 3340–3346 (1998).
Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14, 163–176 (2000).
Van den Steen, P. E., Proost, P., Wuyts, A., Van Damme, J. & Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96, 2673–2681 (2000).
Van den Steen, P. E., Husson, S. J., Proost, P., Van Damme, J. & Opdenakker, G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 310, 889–896 (2003).
Denney, H., Clench, M. R. & Woodroofe, M. N. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and -9: implications for chemotaxis. Biochem Biophys Res Commun 382, 341–347, 10.1016/j.bbrc.2009.02.164 (2009).
Song, J. et al. Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration. Cell Rep 10, 1040–1054, 10.1016/j.celrep.2015.01.037 (2015).
Cauwe, B. et al. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. J Autoimmun 36, 239–252, 10.1016/j.jaut.2011.02.002 (2011).
Fiore, E., Fusco, C., Romero, P. & Stamenkovic, I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21, 5213–5223, 10.1038/sj.onc.1205684 (2002).
Onishi, Y., Fehervari, Z., Yamaguchi, T. & Sakaguchi, S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105, 10113–10118, 10.1073/pnas.0711106105 (2008).
Sheu, B. C. et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61, 237–242 (2001).
Brusko, T. M. et al. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One 4, e7980, 10.1371/journal.pone.0007980 (2009).
Montgomery, A. M., Sabzevari, H. & Reisfeld, R. A. Production and regulation of gelatinase B by human T-cells. Biochim Biophys Acta 1176, 265–268 (1993).
Benson, H. L. et al. Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells. Am J Respir Cell Mol Biol 44, 700–708, 10.1165/rcmb.2010-0125OC (2011).
Abraham, M., Shapiro, S., Karni, A., Weiner, H. L. & Miller, A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 163, 157–164, 10.1016/j.jneuroim.2005.02.001 (2005).
Zeng, L., An, S. & Goetzl, E. J. Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP3 subtype of prostaglandin E2 receptor. J Biol Chem 271, 27744–27750 (1996).
Sato, W. et al. CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis. J Immunol 189, 5057–5065, 10.4049/jimmunol.1202026 (2012).
Weeks, B. S., Schnaper, H. W., Handy, M., Holloway, E. & Kleinman, H. K. Human T lymphocytes synthesize the 92 kDa type IV collagenase (gelatinase B). J Cell Physiol 157, 644–649, 10.1002/jcp.1041570326 (1993).
Leppert, D., Waubant, E., Galardy, R., Bunnett, N. W. & Hauser, S. L. T cell gelatinases mediate basement membrane transmigration in vitro . J Immunol 154, 4379–4389 (1995).
Owen, J. L. et al. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 171, 4340–4351 (2003).
Esparza, J. et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 94, 2754–2766 (1999).
Yakubenko, V. P., Lobb, R. R., Plow, E. F. & Ugarova, T. P. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 260, 73–84, 10.1006/excr.2000.5002 (2000).
Campbell, L. G. et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 5, 517–528, 10.1111/j.1600-6143.2005.00744.x (2005).
Fernández, F. G. et al. Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am J Transplant 5, 671–683, 10.1111/j.1600-6143.2005.00751.x (2005).
Odaka, C., Tanioka, M. & Itoh, T. Matrix metalloproteinase-9 in macrophages induces thymic neovascularization following thymocyte apoptosis. J Immunol 174, 846–853 (2005).
Haidl, I. D., Falk, I., Nerz, G. & Eichmann, K. Metalloproteinase-dependent control of thymocyte differentiation and proliferation. Scand J Immunol 64, 280–286, 10.1111/j.1365-3083.2006.01820.x (2006).
Rybakin, V. & Gascoigne, N. R. Negative selection assay based on stimulation of T cell receptor transgenic thymocytes with peptide-MHC tetramers. PLoS One 7, e43191, 10.1371/journal.pone.0043191 (2012).
Fu, G. et al. Themis sets the signal threshold for positive and negative selection in T-cell development. Nature 504, 441–445, 10.1038/nature12718 (2013).
Gounko, N. V. et al. CRF and urocortin differentially modulate GluRdelta2 expression and distribution in parallel fiber-Purkinje cell synapses. Mol Cell Neurosci 30, 513–522, 10.1016/j.mcn.2005.08.013 (2005).
Descamps, F. J., Martens, E. & Opdenakker, G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 82, 1607–1608 (2002).
Vandooren, J., Geurts, N., Martens, E., Van den Steen, P. E. & Opdenakker, G. Zymography methods for visualizing hydrolytic enzymes. Nat Methods 10, 211–220, 10.1038/nmeth.2371 (2013).
Konkel, J. E. et al. Control of the development of CD8αα+ intestinal intraepithelial lymphocytes by TGF-β. Nat Immunol 12, 312–319, 10.1038/ni.1997 (2011).
Rehg, J. E., Bush, D. & Ward, J. M. The utility of immunohistochemistry for the identification of hematopoietic and lymphoid cells in normal tissues and interpretation of proliferative and inflammatory lesions of mice and rats. Toxicol Pathol 40, 345–374, 10.1177/0192623311430695 (2012).
Zaynagetdinov, R. et al. Identification of myeloid cell subsets in murine lungs using flow cytometry. Am J Respir Cell Mol Biol 49, 180–189, 10.1165/rcmb.2012-0366MA (2013).
Klein, L., Kyewski, B., Allen, P. M. & Hogquist, K. A. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 14, 377–391, 10.1038/nri3667 (2014).
Stritesky, G. L., Jameson, S. C. & Hogquist, K. A. Selection of self-reactive T cells in the thymus. Annu Rev Immunol 30, 95–114, 10.1146/annurev-immunol-020711-075035 (2012).
Carter, J. D., Neel, B. G. & Lorenz, U. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int Immunol 11, 1999–2014 (1999).
Plas, D. R. et al. Cutting edge: the tyrosine phosphatase SHP-1 regulates thymocyte positive selection. J Immunol 162, 5680–5684 (1999).
Burger, M. L., Leung, K. K., Bennett, M. J. & Winoto, A. T cell-specific inhibition of multiple apoptotic pathways blocks negative selection and causes autoimmunity. Elife 3, 10.7554/eLife.03468 (2014).
Anderson, M. S. et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298, 1395–1401, 10.1126/science.1075958 (2002).
Liston, A., Lesage, S., Wilson, J., Peltonen, L. & Goodnow, C. C. Aire regulates negative selection of organ-specific T cells. Nat Immunol 4, 350–354, 10.1038/ni906 (2003).
Smith, C. A., Williams, G. T., Kingston, R., Jenkinson, E. J. & Owen, J. J. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337, 181–184, 10.1038/337181a0 (1989).
Shi, Y. F. et al. In vivo administration of monoclonal antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes. J Immunol 146, 3340–3346 (1991).
Surh, C. D. & Sprent, J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100–103, 10.1038/372100a0 (1994).
Drappa, J., Brot, N. & Elkon, K. B. The Fas protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. Proc Natl Acad Sci USA 90, 10340–10344 (1993).
Matsumoto, K. et al. Defect in negative selection in lpr donor-derived T cells differentiating in non-lpr host thymus. J Exp Med 173, 127–136 (1991).
Kishimoto, H., Surh, C. D. & Sprent, J. A role for Fas in negative selection of thymocytes in vivo . J Exp Med 187, 1427–1438 (1998).
Kurasawa, K., Hashimoto, Y. & Iwamoto, I. Fas modulates both positive and negative selection of thymocytes. Cell Immunol 194, 127–135, 10.1006/cimm.1999.1502 (1999).
Castro, J. E. et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5, 617–627 (1996).
Kishimoto, H. & Sprent, J. A defect in central tolerance in NOD mice. Nat Immunol 2, 1025–1031, 10.1038/ni726 (2001).
Kishimoto, H. & Sprent, J. Negative selection in the thymus includes semimature T cells. J Exp Med 185, 263–271 (1997).
Kishimoto, H. & Sprent, J. Several different cell surface molecules control negative selection of medullary thymocytes. J Exp Med 190, 65–73 (1999).
Villunger, A. et al. Negative selection of semimature CD4(+)8(-)HSA+ thymocytes requires the BH3-only protein Bim but is independent of death receptor signaling. Proc Natl Acad Sci USA 101, 7052–7057, 10.1073/pnas.0305757101 (2004).
Sidman, C. L., Marshall, J. D. & Von Boehmer, H. Transgenic T cell receptor interactions in the lymphoproliferative and autoimmune syndromes of lpr and gld mutant mice. Eur J Immunol 22, 499–504, 10.1002/eji.1830220231 (1992).
Gray, D. H. et al. The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity 37, 451–462, 10.1016/j.immuni.2012.05.030 (2012).
Mitsiades, N., Yu, W. H., Poulaki, V., Tsokos, M. & Stamenkovic, I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61, 577–581 (2001).
Strand, S. et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23, 3732–3736, 10.1038/sj.onc.1207387 (2004).
Fingleton, B., Vargo-Gogola, T., Crawford, H. C. & Matrisian, L. M. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3, 459–468, 10.1038/sj/neo/7900190 (2001).
Powell, W. C., Fingleton, B., Wilson, C. L., Boothby, M. & Matrisian, L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9, 1441–1447 (1999).
Marie, J. C., Liggitt, D. & Rudensky, A. Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25, 441–454, 10.1016/j.immuni.2006.07.012 (2006).
Odaka, C. & Izumiyama, S. Expression of stromelysin-3 (matrix metalloproteinase-11) in macrophages of murine thymus following thymocyte apoptosis. Cell Immunol 235, 21–28, 10.1016/j.cellimm.2005.06.011 (2005).
Vivinus-Nebot, M. et al. Mature human thymocytes migrate on laminin-5 with activation of metalloproteinase-14 and cleavage of CD44. J Immunol 172, 1397–1406 (2004).
Beck, I. M. et al. MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses. PLoS One 3, e2343, 10.1371/journal.pone.0002343 (2008).
Nagase, H., Enghild, J. J., Suzuki, K. & Salvesen, G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29, 5783–5789 (1990).
del Mar Barbacid, M. et al. Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells. Protein Expr Purif 13, 243–250 (1998).
Okumura, Y., Sato, H., Seiki, M. & Kido, H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 402, 181–184 (1997).
Baramova, E. N. et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405, 157–162 (1997).
Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 105, 4796–4801, 10.1073/pnas.0712051105 (2008).
Acknowledgements
We wish to thank Greet Thijs, Kristof Van der Molen, and Nathalie Stienen for the maintenance of the mouse colonies, Dr. Enrico Radaelli for expert help with immunohistochemistry analysis, and Drs. Bernd Arnold, Jennifer Vandooren, and Estefania Ugarte-Berzal for critically reading the manuscript. Specimen processing for immunohistochemical analysis was performed by the Histopathology Laboratory, Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium. The Ventana staining service was provided by InfraMouse (KU Leuven-VIB) through a Hercules type 3 project (ZW09-03). This work was supported by the Geconcerteerde OnderzoeksActies (GOA 2013/015), the Fund for Scientific Research of Flanders (FWO-Vlaanderen) and the Belgian Charcot Foundation. V.R. is a recipient of a Rega Foundation fellowship.
Author information
Authors and Affiliations
Contributions
Designed the study: V.R. and G.O. Performed experiments and analyzed data: V.R., N.V.G., E.M. and G.O. Wrote the manuscript: V.R. and G.O. with input from all authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Gounko, N., Martens, E., Opdenakker, G. et al. Thymocyte development in the absence of matrix metalloproteinase-9/gelatinase B. Sci Rep 6, 29852 (2016). https://doi.org/10.1038/srep29852
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep29852
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.